Celcuity (NASDAQ:CELC) vs. GeneLink (OTCMKTS:GNLKQ) Critical Contrast

GeneLink (OTCMKTS:GNLKQ) and Celcuity (NASDAQ:CELC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a summary of recent ratings for GeneLink and Celcuity, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneLink	0	0	0	0	0.00
Celcuity	0	0	6	1	3.14

Celcuity has a consensus price target of $29.17, indicating a potential upside of 158.34%. Given Celcuity’s stronger consensus rating and higher possible upside, analysts clearly believe Celcuity is more favorable than GeneLink.

Volatility and Risk

GeneLink has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Comparatively, Celcuity has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Valuation and Earnings

This table compares GeneLink and Celcuity”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneLink	N/A	N/A	N/A	N/A	N/A
Celcuity	N/A	N/A	-$63.78 million	($2.61)	-4.33

Profitability

This table compares GeneLink and Celcuity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneLink	N/A	N/A	N/A
Celcuity	N/A	-62.66%	-39.78%

Insider and Institutional Ownership

63.3% of Celcuity shares are owned by institutional investors. 14.2% of GeneLink shares are owned by insiders. Comparatively, 15.8% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Celcuity beats GeneLink on 7 of the 9 factors compared between the two stocks.

About GeneLink

GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.

About Celcuity

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.